Cellarity

Cellarity is a biotechnology therapeutics company based in Somerville, Massachusetts, founded in 2017 by Flagship Pioneering.

The company focuses on drug discovery by addressing whole cell-state dysfunction rather than targeting individual disease proteins. Its mission is to develop medicines that correct dynamic cell states, aiming to tackle complex diseases through innovative approaches. The company utilizes a proprietary drug discovery platform that incorporates single-cell technologies, multi-omics data, and advanced AI models. This platform enables the quantification of cellular behaviors and the prediction of therapeutics that can effectively regulate genetic mechanisms. Cellarity's lead program is a small-molecule fetal hemoglobin inducer, which shows promise as a functional cure for blood disorders. The company is also developing therapies for hematology, immuno-oncology, metabolism, and respiratory diseases. Cellarity primarily operates in the B2B space, serving pharmaceutical researchers and industry partners to enhance drug discovery success rates. Ultimately, its work aims to provide new treatment options for patients with conditions driven by cellular dysfunction.